aPKC was identified as a crucial component in this TGF-β-activated phosphorylation of the Par6 pathway, and its inhibition decreased TGF-β-induced EMT and migration of non-small cell lung cancer (NSCLC) cells [77]. The gene discussed is PARD6A; the disease is non-small cell lung carcinoma.